最新一期业绩显示，2024年三季报，公司实现营业收入21.37亿元，同比-1.36%；净利润1584.12万元， 同比-95.01%，销售毛利率39.50%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)1普瑞眼科-185.3323.162.8062.06亿行业平均 52.8647.733.76166.77亿行业中值49.9041.242.8051.60亿2何氏眼科-165.9550.881.6732.33亿3迪安诊 断-106.4132.041.4098.50亿4光正眼科-95.73227.447.7121.05亿5创新医疗-92.46-129.222.4044.30亿6南华生 物-89.74-118.0813.3833.27亿7国际医学-35.28-34.303.46126.36亿8嘉和美康-30.45-30.452.5645.66亿9皓宸 医疗-24.63-25.375.3523.94亿10美迪西-14.28-14.281.9245.10亿11和元生物-13.18-13.182.2942.84亿 来源：金融界 4月1日，普瑞眼科今日收盘41.48元，上涨1.67%，最新市净率2.80，总市值6 ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-006 成都普瑞眼科医院集团股份有限公司 在使用闲置募集资金暂时补充流动资金期间，公司严格遵守《上市公司监管 指引第2号——上市公司募集资金管理和使用的监管要求》《深圳证券交易所上 市公司自律监管指引第2号——创业板上市公司规范运作》等相关法律、法规和 规范性文件的要求，对募集资金进行了合理的安排与使用，用于暂时补充流动资 金的闲置募集资金仅用于与主营业务相关的生产经营，资金使用安排合理，不影 响募集资金投资项目的正常实施，不存在与募集资金投资项目的实施计划相抵触 的情形，亦不存在变相改变募集资金投向和损害股东利益的情形。 截至2025年4月1日，公司已将用于暂时补充流动资金的闲置募集资金25,000 万元全部提前归还至募集资金专用账户，实际使用期限未超过公司董事会审议通 过之日起12个月，并就上述归还事项及时通知了公司保荐机构和保荐代表人。 特此公告。 成都普瑞眼科医院集团股份有限公司 董事会 二〇二五年四月一日 关于提前归还暂时补充流动资金的闲置募集资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈 ...

最新一期业绩显示，2024年三季报，公司实现营业收入21.37亿元，同比-1.36%；净利润1584.12万元， 同比-95.01%，销售毛利率39.50%。 3月27日，普瑞眼科今日收盘41.56元，下跌5.11%，最新市净率2.80，总市值62.18亿元。 股东方面，截至2024年9月30日，普瑞眼科股东户数11413户，较上次减少528户，户均持股市值35.28万 元，户均持股数量2.76万股。 成都普瑞眼科医院集团股份有限公司是一家集门诊、临床、医疗和医疗技术开发为一体的专业连锁眼科 医疗机构，主营业务为向眼科疾病患者提供专业的眼科医疗服务。公司的产品或服务主要包括屈光项 目、白内障项目、医学视光项目和综合眼病项目，具体包含了屈光手术、医学验光配镜、白内障、青光 眼、斜弱视与小儿眼病、眼底病、眼整形及泪道、角膜病等眼科全科诊疗项目。公司专注于眼科医疗服 务行业10余年，公司已在北京、上海、天津、重庆、成都、武汉、昆明、兰州、合肥、郑州、南昌、乌 鲁木齐、哈尔滨、济南、西安、贵阳、沈阳开办了18家普瑞眼科医院，形成了全国网络布局。公司已具 备开展眼科全科诊疗项目的能力，能够及时有效处理各种眼疾问题，在当 ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-004 成都普瑞眼科医院集团股份有限公司 第三届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 表决情况：同意7票，反对0票，弃权0票。 三、备查文件 1．公司第三届董事会第二十九次会议决议。 特此公告。 成都普瑞眼科医院集团股份有限公司 二、董事会会议审议情况 经与会董事认真审议，表决了以下议案： （一）审议通过《关于为全资子公司申请银行授信提供担保的议案》 公司全资子公司哈尔滨普瑞眼科医院有限公司（以下简称"哈尔滨普瑞"） 拟向上海浦东发展银行股份有限公司哈尔滨分行申请额度为不超过人民币5,350 万元授信，授信期限为1年。公司董事会同意公司为哈尔滨普瑞上述申请银行授 信事项提供连带责任保证担保，担保金额为人民币5,350万元，并授权公司管理 层在上述授信额度内签署担保协议等相关法律文件。 具体内容详见同日在巨潮资讯网（www.cninfo.com.cn）披露的《关于为全 资子公司申请银行授信提供担保的公告》。 成都普瑞眼科医院集团股份有限 ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-005 成都普瑞眼科医院集团股份有限公司 关于为全资子公司申请银行授信提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）于2025年3月24 日召开第三届董事会第二十九次会议以7票同意，0票反对，0票弃权的表决结果 审议通过了《关于为全资子公司申请银行授信提供担保的议案》，同意公司为 本次全资子公司申请银行授信的事项提供连带责任保证担保，并授权公司管理 层在上述授信额度内签署担保协议等相关法律文件。现将相关情况公告如下： 一、担保情况概述 因经营发展需要，公司全资子公司哈尔滨普瑞眼科医院有限公司（以下简 称"哈尔滨普瑞"）拟向上海浦东发展银行股份有限公司哈尔滨分行申请额度 为不超过人民币5,350万元授信，授信期限为1年。公司为哈尔滨普瑞上述申请 银行授信事项提供连带责任保证担保，担保金额为人民币5,350万元。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司 自律监管指引第2号——创业板上市公司规范运作》等相关法 ...

成都普瑞眼科医院集团股份有限公司 证券代码：301239 证券简称：普瑞眼科 公告编号：2025-003 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东股份质押的基本情况 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）近日接到控股 股东成都普瑞世纪投资有限责任公司（以下简称"普瑞投资"）的通知，获悉 普瑞投资将其所持有的公司部分股份办理了股票质押业务。具体事项如下： | 是否 | 为控 | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 是 | 股股 | 否 | 质 | | | | | | | | | | | | | | | | 股 | 东或 | 质 | 本次质押 | 占其所 | 占公司 | 是否 | 为 | 质押 | 押 | 东 | 第一 | 质权 | 押 | | | | | ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-002 成都普瑞眼科医院集团股份有限公司 （一）审议通过《关于制定<市值管理制度>的议案》 为加强公司市值管理工作，进一步规范公司市值管理行为，维护公司、投 资者及其他利益相关方的合法权益，公司董事会同意公司根据《中华人民共和 国公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票上市规则》 《上市公司监管指引第10号——市值管理》等法律、法规、规范性文件和《公 司章程》的相关规定，并结合公司实际情况，制定《市值管理制度》。 表决情况：同意7票，反对0票，弃权0票。 三、备查文件 1．公司第三届董事会第二十八次会议决议。 特此公告。 第三届董事会第二十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）第三届董事会 第二十八次会议通知于2025年1月22日以书面、电子邮件的方式向全体董事发出 并送达，会议于2025年1月26日以通讯方式召开。本次会议应出席董事7人，实 际出席董事7人。会议由董事长徐旭阳 ...

Investment Rating - The report gives a "Recommended" rating for the company, indicating an expectation of stock performance exceeding the market by 10% to 20% within the next six months [9][49]. Core Viewpoints - The company is positioned as a high-quality private ophthalmology medical enterprise in China, with a clear expansion strategy in provincial capitals. Short-term expectations include new hospitals turning profitable, while long-term growth is anticipated from nationwide expansion and increasing demand for medical services due to an aging population [9][49]. - The report highlights the continuous growth in demand for ophthalmic diagnosis and treatment, supported by favorable national policies for private specialized hospitals. The increasing prevalence of eye diseases, particularly among the aging population, is expected to drive market expansion [8][34]. - The company's financial performance is projected to improve significantly as new hospitals enter the profit cycle and existing facilities stabilize. The report forecasts net profits of -0.38 billion, 1.42 billion, and 2.14 billion for 2024, 2025, and 2026, respectively [9][48]. Summary by Sections Section 1: Focus on Ophthalmology Services - The company has completed initial expansion, establishing over 30 specialized ophthalmology hospitals across 23 cities, including major provincial capitals [19][14]. - High-margin projects, particularly refractive surgery, contribute significantly to revenue, with refractive services accounting for 48.73% of total revenue in the first half of 2024 [24][27]. Section 2: Growing Demand for Ophthalmic Services - The number of eye disease patients in China is substantial, with the myopia population increasing from 540 million in 2016 to 660 million in 2020. The penetration rate for refractive surgery remains low, indicating room for growth [8][32]. - National policies are encouraging the development of private medical services, enhancing the operational environment for private ophthalmology clinics [34][35]. Section 3: Economic Recovery and Profit Potential - The company's flagship hospitals have shown strong profitability, with net profit margins of 27.00%, 15.93%, and 20.19% for its top three hospitals in 2023, indicating robust operational capabilities [36][38]. - The report anticipates that as new hospitals mature and begin to turn profitable, the overall net profit margin for the company will improve significantly [36][37]. Section 4: Profit Forecast and Valuation - The company is expected to achieve steady revenue growth, with projected revenues of 27.92 billion, 31.27 billion, and 35.94 billion for 2024, 2025, and 2026, respectively [48]. - The report compares the company's valuation metrics favorably against peers, suggesting significant growth potential as new facilities reach profitability [49][50].

Investment Rating - The investment rating for the company is "Buy" with a current price of 41.02 CNY and a fair value of 53.91 CNY [3][17]. Core Insights - The company is expected to face short-term performance pressure but is anticipated to enter a recovery phase by 2025. The external environment and the pace of expansion are impacting performance negatively in 2024 [7][8]. - The company has a strong position in the private hospital sector in China, benefiting from a differentiated business structure and nationwide layout, which provides significant growth potential [8][16]. Financial Forecast - The company's revenue is projected to be 26.89 billion CNY in 2024, 30.06 billion CNY in 2025, and 33.62 billion CNY in 2026, with corresponding growth rates of -1.1%, 11.8%, and 11.8% respectively [2][17]. - The EBITDA is expected to be 325 million CNY in 2024, 654 million CNY in 2025, and 943 million CNY in 2026 [2]. - The net profit attributable to the parent company is forecasted to be -82 million CNY in 2024, 110 million CNY in 2025, and 284 million CNY in 2026 [2]. Business Segments 1. **Refractive Surgery Business** - The refractive surgery segment is expected to generate revenues of 12.43 billion CNY in 2024, 13.76 billion CNY in 2025, and 15.24 billion CNY in 2026, with a gross margin of 45.0%, 47.0%, and 49.0% respectively [9]. 2. **Optometry Business** - Revenue from the optometry segment is projected to be 3.81 billion CNY in 2024, 4.22 billion CNY in 2025, and 4.67 billion CNY in 2026, with gross margins of 44.0%, 46.0%, and 48.0% respectively [10]. 3. **Cataract Surgery Business** - The cataract segment is expected to generate revenues of 6.20 billion CNY in 2024, 7.13 billion CNY in 2025, and 8.21 billion CNY in 2026, with gross margins of 32.0%, 34.0%, and 36.0% respectively [11][12]. 4. **Comprehensive Eye Disease Business** - Revenue from comprehensive eye disease services is forecasted to be 4.29 billion CNY in 2024, 4.76 billion CNY in 2025, and 5.29 billion CNY in 2026, with gross margins of 10.0%, 12.0%, and 14.0% respectively [13]. Competitive Position - The company is positioned as a leading player in the private hospital sector, with a focus on major cities which have high consumer spending potential. However, it still lags behind industry leaders in terms of revenue scale and profitability [16][17].

Financial Performance Expectations - The company expects a net loss of between 80 million and 120 million RMB for 2024, compared to a profit of 267.91 million RMB in the same period last year[3]. - The projected operating revenue for 2024 is between 2.65 billion and 2.7 billion RMB, a decrease from 2.7178734 billion RMB in the previous year[3]. - The net profit after deducting non-recurring gains and losses is expected to be a loss of 60 million to 90 million RMB, down from a profit of 197.81 million RMB last year[3]. Revenue Challenges - The decline in revenue is attributed to a slowdown in overall demand and intensified industry competition, particularly affecting the refractive and optical projects[5]. - The implementation of national policies for centralized procurement of cataract artificial lenses has pressured the revenue from cataract projects starting from May 2024[5]. Investment and Expansion - The company has accelerated its investment expansion, opening multiple new hospitals in 2022, 2023, and 2024, which are still in the market cultivation phase[6]. - New hospitals are facing challenges due to low local brand influence and the time required to become designated by medical insurance, impacting overall revenue growth[6]. Cost and Profit Margin Impact - Rising costs and expenses, including depreciation, labor costs, and other fixed expenditures, have significantly affected the company's overall profit margins[6]. Caution and Forecast Nature - The company emphasizes that the performance forecast is based on preliminary estimates and has not been audited, with final figures to be disclosed in the 2024 annual report[7]. - Investors are advised to exercise caution and consider investment risks based on the preliminary nature of the performance forecast[7].